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A Ab bs st tr ra ac ct t
The transcription factor Prox1 is the master regulator of lymphatic endothelial cell differentiation
and its expression initiates the morphogenesis of the lymphatic vasculature in the early embryo.
Two new studies now answer some fundamental questions concerning Prox1 biology.
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The bodies of higher vertebrates contain two highly
branched hierarchical networks of endothelial tubules. One
comprises the blood vessels, which provide the conduits for
the systemic circulation and transport cells, gases, nutrients
and waste products to their appropriate targets. The second
endothelial network, the lymphatic vasculature, carries the
lymph - draining tissues of plasma, proteins, particles and
cells that have actively or passively gained access to the
extracellular space [1,2]. Although blood vessels and lym-
phatic vessels are often found in close proximity, direct
contact is avoided, thereby preventing illegitimate shortcuts
between the two networks. Two defined connections do
exist. These enable lymphatic vessels to return their cargo
into the venous circulation after having delivered potential
antigens to the adaptive immune system en route, as the
lymph percolates through the lymph nodes [3].
Despite being first described in the 17th century by Aselli [4],
the lymphatic system until very recently remained the
Cinderella of the vascular family. However, the discovery of
positively identifying marker proteins for lymphatic
endothelial cells (LECs), such as the homeobox transcription
factor Prox1, and the generation of targeted gene deletions
causing lymphatic defects in the mouse have led to un-
precedented progress in our understanding of the biology of
lymph vessel formation.
I In ni it ti ia at ti io on n   a an nd d   m ma ai in nt te en na an nc ce e   o of f   l ly ym mp ph ha at ti ic c   d di if ff fe er re en nt ti ia at ti io on n
Endothelial expression of Prox1 is first detected in mice at
embryonic day (E)10.5 in a dorsal subset of endothelial cells
of the cardinal veins. Prox1-positive cells adopt a lymphatic
identity and under the influence of vascular endothelial
growth factor-C (VEGF-C) bud from the veins, migrate away
and reorganize themselves in the primary lymph sacs of the
jugular and mesonephric region [5]. Prox1-deficient em-
bryos do not accomplish specification of the emerging
lymphatic subpopulation and lack the subsequent upregu-
lation of lymphatic markers. Endothelial cells bud from the
cardinal veins but keep on expressing blood vascular
markers and fail to organize into lymph sacs. The result is a
complete arrest of lymphatic development [6,7]. The knock-
out therefore indicates that Prox1 serves as a master gene for
lymphatic identity, a notion further bolstered by reports
demonstrating that forced expression of Prox1 in blood
endothelial cells (BECs) led to the acquisition of many
lymphatic markers [8,9].
But despite the overwhelming evidence for the role of Prox1
as a lymphatic master regulator, it is still entirely unclear
which molecular mechanism triggers the transcription of
Prox1 during the differentiation of the first LECs and,
equally important, how lymphatic expression of the
transcription factor is maintained throughout life. Withrespect to the first part of this question at least, a study by
Peter Koopman and co-workers (François et al. [10])
published recently in Nature adds an important piece to the
puzzle, by elucidating the role of the transcription factor
Sox18 in the regulation of Prox1.
Mutations in the gene for Sox18 are known to be responsible
for the naturally occurring mouse mutants of the ragged
allelic series [11]. Ragged mutations affect the coat hair and
also cause vascular malfunctions that result in chylous
ascites and edema. In humans, dysfunction of Sox18 is likely
to contribute to the development of the hypotrichosis-
lymphedema-telangiectasia syndrome [12].
Somewhat unexpectedly, targeted inactivation of Sox18 in
the mouse failed to cause vessel defects, which has been
attributed to genetic compensation by the related Sox family
members Sox7 and Sox17 [13-15]. Whereas this knockout
had been generated in a mixed 129/CD1 background, Francois
et al. [10] now report that homozygous Sox18-deficient mice
on a pure-bred C57/Bl6 background develop lethal fetal
edema. Heterozygotes already display patterning and re-
modeling defects of the dermal lymphatic vasculature,
suggesting an important function for Sox18 during
lymphatic development. The absence of polarized Prox1
expression in the cardinal veins of Sox18-deficient embryos
indicates that Sox18 is necessary for Prox1 induction during
the first steps of lymphatic specification. In the cardinal
vein,  Sox18  expression precedes the onset of Prox1
expression by a whole day, also displaying the characteristic
polarized expression pattern in a subset of endothelial cells
within the vessel wall (Figure 1a-c). Furthermore, forced
expression of Sox18 in differentiating endothelial cells
results in the upregulation of lymphatic signature genes,
most notably Prox1. Indeed, a proximal 4.1-kb Prox1 pro-
moter fragment contains two Sox18-binding sites, which are
both necessary for Prox1 expression in vitro and in vivo.
S So ox x1 18 8: :   j ju us st t   o on ne e   d da ay y   o of f   f fa am me e? ?
The study by the Koopman lab raises the question of
whether  Sox18 is the ultimate lymphatic master switch.
Clearly,  Sox18 is part of an essential decision process
upstream of Prox1. However, in contrast to Prox1, Sox18 is
neither indispensable nor likely to act single-handedly
during lymphatic differentiation, as is indicated by the
normal lymphatic development in Sox18-knockout mice on
an outbreed background. Here, the related transcription
factors Sox7 or Sox17 might compensate for the loss of
Sox18, and it could prove revealing to test the C57/Bl6 mouse
for defects in one of these genes. Furthermore, François et
al. [10] demonstrate abundant Sox18 expression in em-
bryonic blood vessels and blood vessels of the newborn
mesentery and skin. This pattern of expression indicates that
Sox18 alone cannot be sufficient for the specification of
lymphatic vessels and points to the existence of an
indispensable, but as yet unidentified, ally of Sox18 during
lymphatic specification.
Intriguingly, and in contrast to Prox1, persistent expression
of Sox18 is not necessary for the maintenance of lymphatic
identity. Obviously, both genes define two different classes
of master switch during tissue specification. Sox18 appears
to act as an inducer of the lymphatic program in the early
embryo and apparently becomes dispensable thereafter.
Prox1 rather exerts a sustaining function and its constant
presence is necessary for the maintenance of the lymphatic
program. The nature of the signals required for this later
phase of Prox1 expression are unclear, but one possibility is
that Prox1 might stimulate its own promoter either directly
or via intermediate transcriptional targets.
L Ly ym mp ph ha at ti ic c   e en nd do ot th he el li ia al l   c ce el ll l   p pl la as st ti ic ci it ty y
More recently, unexpected plasticity of lymphatic endothelial
cells has been reported. Johnson et al. [16] used tamoxifen-
inducible Cre-mediated, and therefore temporally controlled,
inactivation of the Prox1 gene in mice to study the role of
Prox1 in lymphatic vessels at various developmental stages.
Loss of Prox1 from venous lymphatic precursors resulted in
prominent edema and scattered blood-filled vessels at mid-
gestation, reminiscent of constitutive Prox1-knockout mice
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F Fi ig gu ur re e   1 1
Development of lymphatics. ( (a a) ) In response to unknown factors,
lymphatic differentiation is initiated by the polarized expression of Sox18
(yellow nuclei) in venous endothelium. ( (b b) ) Subsequently, Sox18 causes
Prox1 expression (brown nuclei) leading to the exodus of lymphatic
progenitors (yellow cells) from the cardinal veins and the formation of
primary lymph sacs at distant sites. ( (c c) ) Sox18 expression subsides, but
Prox1 expression is maintained in lymphatic endothelium, and lymphatics
form by sprouting from the primitive lymph sacs. ( (d d) ) Genetic ablation of
Prox1 from lymphatic endothelium results in dedifferentiation. Lymphatic-
specific proteins are lost, whereas blood-vessel-specific proteins are re-
expressed (magenta). Blood enters the lymphatics via aberrant
connections, which could be caused by fusion of adjacent vessels (white











sacs[6] (Figure 1d). Similarly, targeting of the Prox1 gene during
later steps of lymphatic development in the embryo led to
the presence of blood in the superficial lymphatics of the
developing skin and in the mesenteric lymphatics.
In keeping with the proposed function of Prox1 as a master
regulator of lymphatic differentiation, loss of Prox1 expres-
sion was accompanied by the loss or downregulation of other
lymphatic markers such as podoplanin, CCL21 (SLC) and
Lyve1. Concomitantly, markers characteristic for the endo-
thelium of blood vessels, such as endoglin or CD34, were
upregulated, and perivascular cells positive for smooth
muscle α-actin, a characteristic feature of blood vessels but
not of lymphatic capillaries, covered the mutant lymphatic
vasculature [3]. Previous work has shown that the endo-
thelial cells of lymphatic capillaries (also termed initial
lymphatics) are connected by discontinuous, button-like
junctions, which presumably facilitate the uptake of cargo
from the extracellular space [17]. Loss of Prox1 compromised
the lymph-specific distribution of the junctional adhesion
molecule VE-cadherin and consequently impaired the
formation of button-like junctions. However, the continuous
and zipper-like junctional pattern seen in the endothelium of
blood vessels was not reacquired in Prox1 mutants, suggest-
ing that LEC dedifferentiation in these mutants is in-
complete or deregulated. Nevertheless, the sum of the find-
ings argues for a change in vessel identity and the partial
adoption of a blood-vessel-like phenotype by the dediffer-
entiated lymphatics.
L Ly ym mp ph ha at ti ic c   e en nd do ot th he el li ia al l   c ce el ll l   p pl la as st ti ic ci it ty y   i in n   h he ea al lt th h   a an nd d
d di is se ea as se e
The study by Johnson et al. [16] adds to the view that
differentiated tissues may retain a surprising degree of
plasticity. Continued expression of Prox1 is required for
maintaining LEC differentiation even in the adult. Con-
versely, lost expression or dysfunction of Prox1 might be
potentially relevant for certain human diseases such as
hereditary lymphedema syndromes, in which malformed
lymphatic vessels are seen [18-20]. Moreover, neoplastic
endothelial cells in angiosarcoma and Karposi’s sarcoma
express both BEC and LEC markers and lack a clear identity
[21-23]. Future work will have to address whether Prox1
plays any part in these or other disease conditions.
The physiological reasons for the remarkable plasticity of the
lymphatic endothelium also remain unclear. Are there any
circumstances during development, growth or tissue re-
generation that might trigger the reprogramming of LECs
and their incorporation into blood vessels? Equally enig-
matic is the question of how the dedifferentiation of LECs
leads to the presence of blood cells within the mutant
lymphatic vessels. This defect is observed in a number of mouse
mutations affecting lymphatic differentiation [20,24-26], and
indicates the presence of aberrant connections between
blood vessels and lymphatic vessels. An important issue to
be resolved is whether such connections are formed by cell-
cell interactions between now identically specified Prox1-
deficient endothelial cells at sites of closest proximity.
Alternatively, dedifferentiated LECs might respond to the
same tissue-derived guidance signals as BECs, so that
sprouts and growing vessels will make contact.
Owing to the availability of targeted mouse mutations and
increasingly refined genetic tools that allow the timed and
tissue-directed precise deletion of genes, the regulation of
blood vessel specification and differentiation is slowly
unfolding. Interestingly, endothelial differentiation appears
to entail an unexpected degree of reversibility, which may be
encouraging news for future attempts towards therapeutic
intervention and regeneration.
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